Isatuximab

Isatuximab, sold under the brand name Sarclisa among others, is a monoclonal antibody medication used for the treatment of multiple myeloma.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Isatuximab, sold under the brand name Sarclisa among others, is a monoclonal antibody medication used for the treatment of multiple myeloma. It is administered by either intravenous injection or subcutaneous injection. It is a CD38-directed cytolytic antibody.

The most common side effects include neutropenia (low levels of neutrophils, a type of white blood cell), infusion reactions, pneumonia (infection of the lungs), upper respiratory tract infection (such as nose and throat infections), diarrhea and bronchitis (inflammation of the airways in the lungs). Isatuximab was approved for medical use in the United States and the European Union in 2020.

The subcutaneous form was approved for medical use in the United States in June 2026.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1371251271 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

14 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.